Related Experiment Video
Updated: Apr 26, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
[Biotherapies in metastatic colorectal cancers in 2014]
Anne Jouinot1, Romain Coriat2, Olivier Huillard1
1AP-HP, groupe hospitalier Cochin-Port-Royal, université Paris-Descartes, service de cancérologie, 75014 Paris, France.
Abstract:
The treatment of metastatic colorectal cancer has been transformed during the last decade with biotherapies, two of them were marketed in 2013. Four agents are monoclonal antibodies, while the fifth agent is a tyrosine kinase inhibitor. Two agents are inhibitors of the EGF-receptor pathway, cetuximab and panitumumab, and have as class-toxicity, cutaneous toxicity. The other three agents are bevacizumab, aflibercept and regorafenib, and interact with angiogenesis, they are associated with a risk of vascular toxicity, mainly hypertension. These agents participate to an improvement of disease control at the metastatic stage, and in some cases, favour the curative surgical resection of metastases. Their use is discussed in multidisciplinary meetings dedicated to gastrointestinal cancers, in the presence of liver surgeons.
Insights
Biotherapies have revolutionized metastatic colorectal cancer treatment. These targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, improve disease control and surgical resection possibilities.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Context:
- Metastatic colorectal cancer (mCRC) treatment has evolved significantly over the last decade.
- Introduction of novel biotherapies, including monoclonal antibodies and tyrosine kinase inhibitors, has transformed mCRC management.
- Two key biotherapies were approved in 2013, marking a new era in mCRC therapy.
Purpose:
- To review the landscape of biotherapies for metastatic colorectal cancer.
- To categorize these agents based on their mechanism of action and associated toxicities.
- To highlight the impact of these therapies on disease control and surgical outcomes.
Summary:
- Four monoclonal antibodies and one tyrosine kinase inhibitor are currently utilized for mCRC.
- Epidermal Growth Factor Receptor (EGFR) pathway inhibitors (cetuximab, panitumumab) are associated with cutaneous toxicity.
- Angiogenesis inhibitors (bevacizumab, aflibercept, regorafenib) carry a risk of vascular toxicity, primarily hypertension.
Impact:
- Biotherapies improve disease control in metastatic colorectal cancer patients.
- These agents can facilitate curative surgical resection of metastases in select cases.
- The use of these advanced therapies is integral to multidisciplinary team discussions for gastrointestinal cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...